Healthcare Industry News: Tranzyme Pharma
News Release - October 22, 2013
Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as Chief Executive Officer and Board DirectorGRAND PRAIRIE, Texas--(Healthcare Sales & Marketing Network)--Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a pipeline of innovative controlled release (CR) products, announced today the appointment of Vipin K. Garg, Ph.D. to the role of Chief Executive Officer, effective immediately. Dr. Garg succeeds Neos Interim Chief Executive Officer, Alan Heller, who will continue serving as Chairman of the Neos Board of Directors. Dr. Garg will also serve as a member of the Neos Board of Directors.
Dr. Garg has over twenty-five years of experience within the biotechnology and pharmaceutical industries in both technical and management positions. He has a proven track record of building and managing both private and publicly traded companies. Before joining Neos Therapeutics, he served as President and Chief Executive Officer of Tranzyme Pharma (NASDAQ:TZYM), where he led the company’s initial public offering in 2011 and its merger with Ocera Therapeutics (OCRX), Inc. in July, 2013.
Neos Therapeutics’ Chairman, Al Heller, stated, “I am excited to welcome Vipin to the Neos team. He brings to us a wealth of strategic, scientific and industry experience. Vipin will work closely with the organization to obtain FDA approval of our existing pipeline, and expand the use of our proprietary controlled release technologies to create additional CR orally disintegrating tablets and CR liquids to bring to market.”
Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex Bioscience, Inc. (now Curacyte AG of Munich, Germany), and held senior management positions at DNX Bio-Therapeutics, Inc. until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Dainippon Sumitomo Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare Corporation).
Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from New Delhi, India in 1978. He was a member of the U.S. Presidential Mission to India led by President Bill Clinton in March, 2000. He is a past board member of the North Carolina Biotechnology Center and currently serves on the Executive Committee of CED (formerly the Council for Entrepreneurial Development). He was the recipient of the Ernst & Young Entrepreneur of the Year 2009 Award, Carolinas Region.
"I am delighted to join Neos Therapeutics," said Dr. Garg. "Neos has developed proprietary controlled release technologies. These technologies are being utilized to develop a pipeline of novel ADHD products which will advance significantly in the next 12-18 months. Building on the approval of a generic of Tussionex®, an extended release cough cold product developed utilizing the Neos technology and manufactured exclusively by Neos, the company is well positioned for growth. I look forward to working with the Neos team to expand the pipeline to additional opportunities including prescription, over-the-counter and veterinary products in a wide range of therapeutic areas. “
About Neos Therapeutics
Neos Therapeutics Inc. is a specialty pharmaceutical company focused on the development, manufacture and sale of FDA approved drug products that utilize the company’s proprietary delivery technologies. The Neos drug products are being developed using the Dynamic Time Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking™ (RDIM™) technologies that deliver controlled release (CR) small molecule active pharmaceutical ingredients (APIs) in either liquid or orally disintegrating tablet (ODT) dosage forms. By utilizing APIs that are FDA-approved and known to be safe and effective, Neos can reduce development and regulatory risk and efficiently advance targeted proprietary Rx products through the FDA’s New Drug Application (NDA) approval process. For more information, visit www.neostx.com.
Dynamic Time Release Suspension®and DTRS® are registered trademarks of Neos Therapeutics, LP, an affiliate of Neos Therapeutics, Inc., and Rapidly Disintegrating Ionic Masking™ and RDIM™ are trademarks of Neos Therapeutics, Inc.
This press release contains certain ''forward-looking statements'' that include projections and may also include words such as ''may'', ''will'', ''expects'', ''believes'', ''anticipates'', ''plans'', ''estimates'', ''seeks'', ''could'', ''intends'', and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.
Source: Neos Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.